A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Conditions: Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarian Cancer; BRCA2 Mutation; ER+ Breast Cancer; Castrate Resistant Prostate Cancer; BRCA1 Mutation; BRCA Mutation; Endometrial Cancer; Colorectal Cancer; Gastric Cancer
Interventions: Drug: ETX-19477
Sponsors: 858 Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 3, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments